The duration (treatment and follow up) of the individual studies depended on the type of study (supplementary data). The first three clinical trials were single dose treatments (METAOD001 - METAOD003); the longest was a phase IIb clinical trial (METAOD006) with a four weeks run-in phase, followed by a six months treatment phase and a 30 day follow-up phase.
In ob/ob mice, both AOD9604 and hGH reduced both white and brown adipose tissue mass and increased β3-AR RNA expression. This suggested that an elevation inβ 3-AR RNA expression is associated with increased fat metabolism and a reduction in the fat tissue mass in the ob/ob mouse model. Obese mice have lower levels ofβ 3-AR expression in their adipose tissues than lean mice, shown in this study and others (14). The ability of AOD9604 and hGH to increase the level ofβ 3-AR RNA expression in obese mice to a level that is comparable to those in lean mice is an exciting finding. However, it must also be considered that both hGH and AOD9604 may influence the expression of other members of the adrenergic pathway, such as the β1-ARs, hormonesensitive lipase, and signaling proteins, which are all expressed in adipose tissue and associated with lipolysis. The importance of the change inβ 3-AR expression with AOD9604 and hGH in humans is not established and will depend on the use of potent and selectiveβ 3-AR agonists that are active at the human receptor.
A synthetic analogue (AOD9604) of the lipolytic domain of human growth hormone (hGH) has been studied for its metabolic actions in obese Zucker rats. Daily treatment with an oral dose of AOD9604 of 500 microg/kg body weight for 19 days reduced over 50% (15.8 +/- 0.6 vs. 35.6 +/- 0.8 g) body weight gain of the animals in comparison with the control. The adipose tissues of the AOD9604--treated animals were found to have an increase in lipolytic activity. In contrast to chronic treatment with intact hGH, chronic treatment with AOD9604 showed no adverse effect on insulin sensitivity of the animals, as demonstrated with euglycemic clamp techniques. The results in the present study suggest that the analogue of the hGH lipolytic domain may have the potential to be developed into an orally usable and safe therapeutic agent for obesity.
When combined with the other IGF-1 and growth hormone boosting strategies you’ve just discovered – such as eating adequate calories, heavy weight training, 7-9 hours of sleep per 24 hour cycle, adequate mineral intake and moderation of alcohol intake – these additional strategies will ensure you get all the anabolic effects of IGF-1 and growth hormone without having to resort to needles, syringes, prescriptions, online pharmacies and potentially dangerous self-experimentation.
Another benefit of CJC 1295 is its ability to promote slow wave sleep. Slow wave sleep is also known as deep sleep and is the portion of sleep responsible for the highest level of muscle growth and memory retention. SWS decreases significantly in older adults and also with people who tend to exercise later in the evening. Clinical studies have shown that a once-daily administration of CJC 1295 normalizes the GHRH response and can induce significantly deeper sleep.
Many patients use Ipamorelin short term (3-6 months) for fat loss benefits and overall improvements in body composition. Ipamorelin increases fat metabolism, so when age starts to become a factor in a person’s ability to lose weight, this peptide can create a more efficient and sometimes faster process. Patients that are also physically active tend to notice even faster benefits while using Ipamorelin, as it aids recovery from workouts and allows for faster progression and typically more fat loss. Once a patient’s desired weight has been achieved, Ipamorelin use can be discontinued, and weight maintenance can be achieved through diet and lifestyle changes.
CJC-1295 increases the production of growth hormone as well as IGF-1 – which has anabolic effects in adults. However, it does not increase the levels of prolactin – high levels of which can create impotence and mental health problems in men. By increasing these two hormones, it enhances protein production in the body, which in turn, boosts muscle mass. It also induces lipolysis – the breakdown of fat tissue, boosts recovery from injuries, increases bone density, and also reduces aging factors like skin wrinkles. It can also stimulate cell growth, due to which it can be used to treat withered tissue or organs.
It's really tough to tell. It has properties that suggest it might be, but the evidence simply doesn't exist to make any definitive claims. AOD9604 was designed as a modified fragment of growth hormone. The original intention was to create a drug that has the effect on adipose (fat) cells of growth hormone, without the other effects. This sort of drug development is littered with failures, because replicating a sequence of amino acids is not the same as replicating a protein and its effects. It's not just the chemical composition of a protein that determines how it interacts with other molecules (especially endocrine receptors, like those that growth hormone acts on), but also how that protein folds. There's only really one way to tell what your compound actually does, and that's to try it out.
recently studies found that in the process of destroying the fat cells, it shook stem cells which are inside the fat cells giving rise to new found REGENERATIVE POWERS of AOD. It works well at regenerating ligaments after significant damage and muscle repair, by increasing cartilage and collagen production in your joints. It has also been seen to improve bone density which can have positive effects on osteoporosis.
The world is talking about peptides’ unique ability to build new muscle cells. The amino acids used in the formation of muscle are allowed to combine due to the action of peptide bonds. Professional athletes and healthcare professionals alike swear by them, and these supplements are known to naturally boost the metabolism, which can increase energy and overall happiness.